DaVita Labs Appoints New Vice President and General Manager
December 01 2011 - 11:34AM
Business Wire
DaVita Labs, a chronic kidney disease specialty laboratory,
today announced the appointment of Leslie Mirani as DaVita Labs’
new vice president and general manager.
Mirani brings to DaVita Labs™ more than 25 years experience in
commercial sales and marketing – primarily renal-focused – in the
pharmaceutical industry. Mirani’s previous roles included working
for Human Genome Sciences as an immunology sales director and as
vice president for Amgen’s nephrology business unit for 18 years.
She graduated from Ohio State and is a registered clinical
dietician.
“Leslie’s extensive background will give us the momentum to move
forward with our future goals and continue to provide great
service, quality, technology and education to keep us at the front
end of new developments within the industry,” said DaVita Labs
President Chris Rucker.
DaVita Labs has 86,700 square feet dedicated to its
state-of-the-art clinical diagnostic laboratories between its two
locations in Fort Lauderdale and DeLand, Fla. The laboratories
feature the latest in renal-specific methodology and technology for
delivering quality test results. The DaVita Labs clinical
laboratory team is led by experienced scientists and pathologists,
and receives formal guidance from top nephrologists in the
industry.
DaVita and DaVita Labs are trademarks or registered trademarks
of DaVita Inc. All other trademarks are the property of their
respective owners.
About DaVita Labs
DaVita Labs, a division operating within DaVita
Inc., provides quality, on-time, accurate results to help
effectively identify and manage kidney patients across the nation.
As a cutting-edge chronic kidney disease (CKD) specialty
laboratory, DaVita Labs features the latest in end stage renal
disease-specific methodology and technology for delivering quality
dialysis test results. DaVita Labs is fully accredited by the
federal and state governmental agencies, and the College of
American Pathologists. For more information, please visit
www.davitalabs.com or call 877-200-3181.
About DaVita
DaVita Inc., a Fortune 500® company, is a leading provider of
kidney care in the United States, delivering dialysis services to
patients with chronic kidney failure and end stage renal disease.
DaVita strives to improve patients’ quality of life by innovating
clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services.
As of Sept. 30, 2011, DaVita operated or provided administrative
services at 1,777 dialysis facilities, serving approximately
138,000 patients. DaVita supports numerous programs dedicated to
creating positive, sustainable change in communities around the
world. The company’s leadership development initiatives and social
responsibility efforts have been recognized by Fortune, Modern
Healthcare, Newsweek and WorldBlu. For more information, please
visit www.davita.com.
DaVita (NYSE:DVA)
Historical Stock Chart
From May 2024 to Jun 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2023 to Jun 2024